Navigation Links
Panmira and FLAP LLCs Spun Out of Amira Pharmaceuticals
Date:9/8/2011

SAN DIEGO, Sept. 8, 2011 /PRNewswire/ -- Panmira Pharmaceuticals, LLC and FLAP, LLC, today announced their formation around certain assets spun out immediately preceding the acquisition of Amira Pharmaceuticals, Inc. (Amira) by Bristol-Myers Squibb Company (NYSE: BMY).  Panmira Pharmaceuticals received a number of assets, including Amira's DP2 antagonists, AM211 and AM461, both of which have successfully completed Phase I clinical studies.  FLAP, LLC is a non-operating company with rights to future milestones and royalties from Amira's 2008 licensing deal with GlaxoSmithKline related to the 5-lipoxygenase-activating protein (FLAP) inhibitor program.

"Now that we have successfully completed the sale of Amira to Bristol-Myers Squibb Company, a subset of the former Amira team will focus on completing our partnership efforts for the DP2 program," said Bob Baltera, Chief Executive Officer of Panmira Pharmaceuticals.  "We believe that spinning out these assets will be the best way to maximize their value for Amira's shareholders, and we look forward to accomplishing this goal."

Hari Kumar, Ph.D., Chief Business Officer, added, "Clinical trial results have demonstrated a dose proportional pharmacodynamic (PD) effect and good safety profiles for both AM211 and AM461.  These compounds are primed and ready for Phase II exploration in a number of clinical settings, including asthma, chronic obstructive pulmonary disease (COPD) and eosinophillic esophagitis.  We look forward to having the right partner to help make these plans come to fruition."

While there are no DP2 selective antagonists approved for therapeutic use, there is a strong scientific rationale for the target to be a novel, potentially disease-modifying treatment of asthma, COPD and allergic rhinitis. DP2, also known as chemoattractant receptor-homologous molecule expressed in Th2 lymphocytes (CRTH2), is a high affinity receptor for the prostaglandin D2 and is impli
'/>"/>

SOURCE Panmira Pharmaceuticals, LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Amira Pharmaceuticals to Present Preclinical Data on AM152 , an LPA1 Receptor Antagonist, at the Annual Meeting of the American Thoracic Society
2. Amira Pharmaceuticals Announces Completion of Phase 1 Clinical Study for AM152, A Novel LPA1 Receptor Antagonist
3. Amira Pharmaceuticals Receives Orphan Drug Status for a Novel LPA1 Antagonist, AM152, for the Treatment of Idiopathic Pulmonary Fibrosis
4. Amira Pharmaceuticals Announces the Nomination of an Orally Available Pre-Clinical Candidate in a New LPA-Related Program, an Autotaxin Inhibitor
5. Amira Pharmaceuticals Announces Initiation of Phase I Clinical Trial for AM152, A Novel LPA1 Antagonist
6. Amira Pharmaceuticals Announces IND Submission for Novel LPA1 Antagonist, AM152, for Potential Use in Fibrotic Diseases
7. Amira Pharmaceuticals Named One of Most Promising Biotech Companies by FierceBiotechs Annual Fierce 15
8. Visage Imaging Releases Amira 5.3
9. Amira Announces AM103 and AM803 Patent Grant in the United Kingdom
10. Amira Announces Second DP2 Antagonist Patent Grant in the United Kingdom
11. Anti-Fibrotic Data from Amira Pharmaceuticals LPA1 Receptor Antagonist Program Published in the British Journal of Pharmacology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... YORK , Aug. 20, 2014 ... is available in its catalogue: Global ... http://www.reportlinker.com/p01375204/Global-Coatings-for-Medical-Devices-Industry.html This report ... Devices in US$ Million by the following Product ... Nanotechnology Coatings. The report provides separate comprehensive analytics ...
(Date:8/20/2014)... and PHOENIX , ... established to bring cutting-edge next-generation sequencing and proteomic ... patients, today announced a collaboration with TESARO, Inc.  ... characterize patient tissue samples from clinical trials to ... resistant to TESARO,s TSR-011.  This may lead to more ...
(Date:8/20/2014)... , Aug. 20, 2014 ApolloDx™ today announced ... platform during a special event at the company,s office ... on September 5, 2014. The event, which will start ... ApolloDx website, www.apollodx.com .    "We ... said Jared Bauer , Co-Founder and Managing Partner ...
Breaking Medicine Technology:Global Coatings for Medical Devices Industry 2Global Coatings for Medical Devices Industry 3Global Coatings for Medical Devices Industry 4Global Coatings for Medical Devices Industry 5Global Coatings for Medical Devices Industry 6Global Coatings for Medical Devices Industry 7Global Coatings for Medical Devices Industry 8Global Coatings for Medical Devices Industry 9Global Coatings for Medical Devices Industry 10Global Coatings for Medical Devices Industry 11Global Coatings for Medical Devices Industry 12Global Coatings for Medical Devices Industry 13Global Coatings for Medical Devices Industry 14Global Coatings for Medical Devices Industry 15Global Coatings for Medical Devices Industry 16Global Coatings for Medical Devices Industry 17Global Coatings for Medical Devices Industry 18Global Coatings for Medical Devices Industry 19Global Coatings for Medical Devices Industry 20Global Coatings for Medical Devices Industry 21Paradigm Announces Molecular Profiling Collaboration with TESARO, Inc. 2
... Inc. (Nasdaq: ENZN) announced today that four,posters containing ... Meeting of the American Association for Cancer Research,(AACR) ... 2007 in Los Angeles, CA., Details of the ... EZN-2208, a novel polyethyleneglycol-SN38,conjugate, has potent antitumor activity ...
... 13, 2007 - Point Therapeutics, Inc.,(NASDAQ: POTP) today ... 2007 Annual Meeting of the American,Association for Cancer ... 14-18, 2007. The AACR poster presentations report,on preclinical ... details for the AACR presentations are as,follows: , ...
Cached Medicine Technology:Enzon to Present Preclinical Data From PEG-SN38 and PEGylation,Technology Studies at AACR Meeting 2
(Date:8/21/2014)... 21, 2014 Denver marketing agency ... for the American Lung Association in Colorado’s 2014 ... welcome Webolutions as a sponsor,” said Curt Huber, Chief ... Executive Director, American Lung Association in Colorado, “and we’re ... in this role they’ve defined.” , Webolutions has also ...
(Date:8/21/2014)... August 21, 2014 If chocolate is good ... will soon be very happy and healthy. Tracie is the ... Break ” contest. She and three of her coworkers will ... luxuriate at the world-famous Chocolate Spa® at The Hotel Hershey® ... third year working in the ambulatory surgery center at Connecticut ...
(Date:8/21/2014)... Rockville Centre, NY (PRWEB) August 21, 2014 ... injury law firm with over 25 years of experience ... dangerous prescription drugs and defective medical devices, announces the ... offer information to those women who believe they have ... The site offers valuable information about the severe adverse ...
(Date:8/21/2014)... Michael E. Steuer , local doctor ... to the Bluff City with recent philanthropy at local synagogue. ... the United States,” says friend and Rabbi David Julian of ... such as providing in-house for the needy and teaching Hebrew ... in the local synagogue. And to remain close with the ...
(Date:8/21/2014)... August 21, 2014 InSilico ... interventions and addressing the challenges of a ... OncoFinder, for signalome-wide pathway analysis. This ... cross-platform analysis of gene expression data obtained ... published in the journal Frontiers in Molecular ...
Breaking Medicine News(10 mins):Health News:Denver Marketing Agency Webolutions Named Inspirational Sponsor for 2014 Run the ‘Rocks 5K 2Health News:Denver Marketing Agency Webolutions Named Inspirational Sponsor for 2014 Run the ‘Rocks 5K 3Health News:Connecticut Nurse Wins a Sweet Prize from California Casualty 2Health News:Rottenstein Law Group LLP Announces Launch of WeHelpWomen.com 2Health News:OncoFinder, a new algorithm for minimizing errors in high-throughput transcriptome analysis 2
... INDIANAPOLIS, Sept. 14 In conjunction with today,s announcement ... to patients, Eli Lilly and Company (NYSE: ... Center of Excellence and its five business units: oncology, ... These leaders will provide improved line of sight to ...
... in dementia care is not so much related to equipment ... communication problems and misunderstandings. This is shown in a new ... Sweden. Dementia not only affects the memory and other ... to walk. ,The symptoms of dementia are very individual ...
... , AHIP to leverage MedAssurant,s datasets and ... affordability of healthcare. , , WASHINGTON, ... Inc., announced today that MedAssurant, through its healthcare data analytics ... quality and effectiveness of treatments. , , ...
... boosting the odds, experts say, , MONDAY, Sept. 14 (HealthDay ... the odds that a child will develop asthma or allergies, ... spent more than 1,000 hours swimming in chlorinated pools, either ... of having asthma than did teens who primarily swam in ...
... , , NCCN is ... forum to discuss the regulatory and operational aspects of research ... improvements can be made. Scheduled for October 26 - 27 ... and panel discussions on topics that challenge the conduct of ...
... Schizophrenia is a major public health problem. Affecting almost ... economic and social toll in addition to the distress, ... disease. Elements of the disease are present from birth, ... becomes fully expressed in early adulthood with long-lasting implications ...
Cached Medicine News:Health News:Lilly Names New Business Leaders 2Health News:Lilly Names New Business Leaders 3Health News:Lilly Names New Business Leaders 4Health News:Lilly Names New Business Leaders 5Health News:Lilly Names New Business Leaders 6Health News:Lilly Names New Business Leaders 7Health News:Lilly Names New Business Leaders 8Health News:Communication problems in dementia care cause physical strain 2Health News:MedAssurant to Support AHIP's Research Capabilities 2Health News:Chlorine in Pools Raises Kids' Asthma, Allergy Risk 2Health News:Chlorine in Pools Raises Kids' Asthma, Allergy Risk 3Health News:NCCN Holds Oncology Research Best Practices Conference 2Health News:NCCN Holds Oncology Research Best Practices Conference 3Health News:The future of schizophrenia 2Health News:The future of schizophrenia 3Health News:The future of schizophrenia 4Health News:The future of schizophrenia 5
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: